1-4 of 4
Jiali Cheng
Close
Sort by
Journal Articles

Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma

Jiali Cheng, Jue Wang, Xia Mao, Wei Mu, Shijia Sun, Xiaoxi Zhou, Liang Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 6863.
https://doi.org/10.1182/blood-2023-184370
Published: 2023
Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Zongcheng Li, Lei Zhao, Yuanyuan Zhang, Li Zhu, Wei Mu, Tong Ge, Jin Jin, Jiaqi Tan, Jiali Cheng, Jue Wang, Na Wang, Xiaoxi Zhou, Liting Chen, Zhilin Chang, Chen Liu, Bian Zhilei, Bing Liu, Lilin Ye, Yu Lan, Liang Huang, Jianfeng Zhou
Journal: Blood
Blood (2023) 142 (Supplement 1): 4851.
https://doi.org/10.1182/blood-2023-178624
Published: 2023
Journal Articles

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Jin Jin, Jiali Cheng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, Tianjiao Liu, Jiao Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 10265–10266.
https://doi.org/10.1182/blood-2022-156710
Published: 2022
Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Clinical Trials & Observations
Na Wang, Xuelian Hu, Wenyue Cao, Chunrui Li, Yi Xiao, Yang Cao, Chaojiang Gu, Shangkun Zhang, Liting Chen, Jiali Cheng, Gaoxiang Wang, Xiaoxi Zhou, Miao Zheng, Xia Mao, Lijun Jiang, Di Wang, Qiuxiang Wang, Yaoyao Lou, Haodong Cai, Dandan Yan, Yicheng Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang
Journal: Blood
Blood (2020) 135 (1): 17–27.
https://doi.org/10.1182/blood.2019000017
Published: 2020
Includes: Supplemental data